Radiation Treatments for Hodgkin's Lymphoma Increases Breast Cancer Risk

Marie L. De Bruin, Ph.D., of the Netherlands Cancer Institute in Amsterdam, and colleagues studied 1,122 females who had been treated for Hodgkin's lymphoma with radiation prior to the age of 51 years. The incidence of breast cancer in the cohort was compared to the general population.

Overall, the researchers found that the incidence of breast cancer in the study cohort 30 years after Hodgkin's lymphoma radiation treatment was 19 percent, while for those treated before age 21 years, the incidence was 26 percent. Risk of breast cancer varied by radiation treatment type, with mantle field irradiation of the axillary, mediastinal, and neck nodes producing a 2.7-fold increased risk compared with mediastinal irradiation at similar doses. Women with 20 or more years of ovarian function after radiation therapy at age less than 31 years had higher risk of breast cancer than those with fewer than 10 years of ovarian function.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap